iCAD plans to supply lung cancer software

Article

Software developer iCAD and image processing specialist TeraRecon have signed a nonexclusive product licensing and distribution agreement under which TeraRecon will develop a new server-based product offering to include iCAD lung cancer detection,

Software developer iCAD and image processing specialist TeraRecon have signed a nonexclusive product licensing and distribution agreement under which TeraRecon will develop a new server-based product offering to include iCAD lung cancer detection, analysis, and tracking software. Product release is expected in 2005. The stand-alone server product will work in concert with existing PACS and DICOM review equipment, as well as other products in the TeraRecon Aquarius product line. The three-year agreement provides for worldwide distribution through TeraRecon's direct sales force, independent resellers/distributors, and OEM partnerships. The companies have agreed to work together to obtain the FDA approvals necessary for U.S. distribution.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.